Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Investor Presentation (May 2015)

19 slides from Sucampo Pharmaceuticals's investor presentation, May 20, 2015

  1. Slide 1: Sucampo Pharmaceuticals, Inc.

    = Sucampo Pharmaceuticals, Inc. BS Global fealtiicals Stan Miele President, ¢ $ sucAMPO ‘The Science of Innovation

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements litigation andior regulatory actions. Which Sucampo incorporates by reference. @ sucAMPO 2 é ‘The Selence of Innovation

  3. Slide 3: Sucampo Overview

    Sucampo Overview = Sucampo i lobal biophai y built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients = Proven Ff successful ical product 1 = AMITIZA® i: gship product: differentiated profile in an attractive hat wit t need cy g foundation =

  4. Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company

    Revenue & Market Value = Focus efforts strengthen vera capabilities + Team + Development capability Secure and grow AMITIZA, revenues + Efforts to ores consistent and stant rowth + Global partn ripe @ cnacta rete of patent litigatio Optimize investment in current ici + Life cycle management (LCM) +

  5. Slide 5: AMITIZA (lubiprostone)

    | = “2 ° amitiza lubiprostone e $ sucamPo ‘The Science of Innovation

  6. Slide 6: AMITIZA is a Unique and Highly-Differentiated Product

    AMITIZA is a Unique and Highly-Differentiated»Product 3 patient types Ww . * CIC: Chronic Idiopathic Constipation * IBS-C: * OIC: = Only i 1. Increases intestinal fluid secretion i function Key product characteristics Locally- Ie} . safety pro’ * No black oom warning $ sUCAMPO é ‘The Selence of Inno

  7. Slide 7: Brand TRx by Category

    Tarte warty Annual: (Cituceh, Saline lx & mineral ol 50M TRx & Sanefiser) _(orbtol& Mik of Mag} $4.48 Linaclotide \ Fit Enomas (1%) san \, alr — Heo 6 ‘ ee RON leritant- ‘stimulant lax (ExLax, Dulcoiax) Bentyl (other IBS) ‘Stool softener ‘without stimulant laxatives (Colace) Osmi Prep, PEG preps nal

  8. Slide 8: TRx Scripts

    TRx Scripts 1,350,000 9 1,300,000 1,250,000 1,200,000 1,150,000 YTD growth 6% 2012 20132014 TRx Scripts’ 600,000 7,652 2012 aUnits “Based on Management assumption of 4 capsules portrx 4,241,304 489,843, 2013, 2014 $ SUCAMPO ‘The Science of Innovation

  9. Slide 9: Levers Will Drive AMITIZA Outsized Growth

    evers Will Drive AMITIZA-Outsized, Growth v Underpenetrated markets with unsatisfied patients Expanded Takeda agreement Physician Targeting prc 4A & OR OIC driving = 30% of brand sales v Yearly Increases v Takeda Tene onatee + Net sales ts revenue spit on brand lubiprost incl. LO Y Agreement with Pa

  10. Slide 10: New Market Opportunities

    New Market Opportunities U.K. cic; OIC under review Switzerland us. CIC and OIC CIC, IBS-C and oic Latin America TBD Takeda is #1 Gl company world wide Takeda has rights to all markets except Japan (Mylan) and China Py SUCAMPO reece congeim tn us, oun cea ay foun uaewory. Nenenenenrspon rears. coin

  11. Slide 11: AMITIZA Life Cycle Management

    AMITIZA Life Cycle Management 1. New Formulation capsules, or naso-gastric tube fed patients swallowing pills + Next step: Phase 3 commence 2H 2015 » US Prevalence: 18% of pediatric population (13.5M) » Unmet need: No FD, * Current formulation: capsule formulation e $ sucamPo ‘The Science of Innovat

  12. Slide 12: Sucampo

    ¢ $ sucAMPO ‘The Science of Innovation

  13. Slide 13: At-A-Glance: Sucampo Pipeline

    At-A-Glance: Sucampo Pipeline [ CLINICAL FOCUS | ‘STAGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS Leap comPouNnDs [ress punse 2 punses Lubjprostone —Pediatric Functional Constipation (6 years-17 years) Lifecyele Management Lubjprostone —Altemate Formulation — Pediatric Functional Constipation (Gmonth

  14. Slide 14: Supplementing Existing Pipeline

    Supplementing Existing Pipeline e $ sucamPo ii ‘The Science of Innovation

  15. Slide 15: Sucampo

    ¢ $ sucAMPO ‘The Science of Innovation

  16. Slide 16: Total Revenue

    Total Revenue AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes} WV Notes Payable Total Revenue AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes): Net Income $25M - $30M. | EPS | $0.55 - $0.65 | $ sucAMPO ‘6 ‘The Science of Innovation

  17. Slide 17: Upcoming Milestones

    Upcoming Milestones vent Global partnership agreement for AMITIZA. v Updated on AMITIZA alternate formulation and PFC development T Filed AMITIZA for approval in Canada T Initiated MRP to secure approval for AMITIZA (CIC) in additi E kets Ni ‘Decision made on ion channel activator program for LSS T

  18. Slide 18: Investment Highlights

    Investment Highlights = Lead pl with a ee unmet pele BI hi ide alobal Wh and.del teed revenue pls bn = Multiple | ilabl dri inable long term growth 7 i i foundation i i maximizes franchise value = Strong financial perf it! heet and cash position = Deep with p p product development ¢$ SuCAMPO é ‘The

  19. Slide 19: Sucampo

    ¢ $ sucAMPO ‘The Science of Innovation

Sucampo Pharmaceuticals — Investor Presentation (May 2015) on 6ix